Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00393939 · ClinicalTrials.gov registry record · Phase 3
Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer
A Phase 3 study of Breast Neoplasms, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 594
- Enrollment target
- 20
- Study locations
NCT00393939: Completed Phase 3 study of Breast Neoplasms, sponsored by Pfizer.
NCT00393939 is a Phase 3 study of Breast Neoplasms that has completed, run by Pfizer. The registered enrollment target is 594 participants, roughly in line with the 563-participant average among 97 other Breast Neoplasms trials with a reported enrollment target. The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00393939, a Phase 3 study of Breast Neoplasms, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 594 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of sunitinib combined with docetaxel versus docetaxel, administered as first-line treatment, in patients with unresectable locally recurrent or metastatic breast cancer.
Primary Outcome
PFS defined as time from date of randomization to date of the first documentation of objective tumor progression or death due to any cause, whichever occurred first. PFS calculated as (Months) = (first event date minus randomization date plus 1) divided by 30.4.
Conditions Studied
Interventions
- DRUG Taxotere
- DRUG Sunitinib malate
Study Locations (20)
Texas
- Pfizer Investigational Site - Beaumont
- Pfizer Investigational Site - Burleson
- Pfizer Investigational Site - Cleburne
- Pfizer Investigational Site - Fort Worth
- Pfizer Investigational Site - Mineral Wells
- Pfizer Investigational Site - Weatherford
Other
- Pfizer Investigational Site - Burnos Aires
- Pfizer Investigational Site - Salzburg
- Pfizer Investigational Site - Vienna
Victoria
- Pfizer Investigational Site - Brighton
- Pfizer Investigational Site - Malvern
- Pfizer Investigational Site - Ringwood East
Buenos Aires
- Pfizer Investigational Site - La Plata
- Pfizer Investigational Site - Pergamino
California
- Pfizer Investigational Site - Berkely
Louisiana
- Pfizer Investigational Site - Shreveport
New South Wales
- Pfizer Investigational Site - Tweed Heads
Queensland
- Pfizer Investigational Site - Redcliffe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 594 participants |
| Start Date | 2007-02 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
What the finished NCT00393939 record still lists
NCT00393939 is an interventional study that assigns participants to a tested intervention. The registered 594 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 563-participant average among 97 other Breast Neoplasms trials with a reported enrollment target.
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Taxotere is the first listed.
NCT00393939 names 20 study sites across 10 states, led by Texas, Other, Victoria.
Frequently Asked Questions
What is clinical trial NCT00393939 about?
NCT00393939 is a clinical study titled "Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer". This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of sunitinib combined with docetaxel versus docetaxel, administered as first-line treatment, in patients with unresectable locally recurrent or metastatic breast cancer.
What is the current status of trial NCT00393939?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 594 participants. The study started on 2007-02. Estimated completion is 2011-07.
What conditions does trial NCT00393939 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT00393939?
The interventions under investigation include: Taxotere (DRUG), Sunitinib malate (DRUG).
Who is sponsoring clinical trial NCT00393939?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00393939 being conducted?
This trial has 20 study locations across California, Louisiana, Texas, Buenos Aires, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00393939's enrollment target sits among peer trials
594 19th of 97 higher than 79 of 97 other Breast Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RECRUITING · Phase 3
-
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RECRUITING · Phase 3
-
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
RECRUITING · Phase 3
-
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
RECRUITING · Phase 3
-
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
RECRUITING · Phase 3
-
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04701684 · 594 participants · NA
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
- NCT05491213 · 594 participants · NA
TELESCOPE- TELEhealth Shared Decision-making COaching
- NCT05867420 · 594 participants · Phase 1
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
- NCT06890884 · 594 participants · Phase 2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia